LinkedIn Profile

Access Critical Diagnostics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:criticaldiagnostics 2707190 Dec 3rd, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Dec 3rd, 2020 09:44AM Dec 3rd, 2020 09:44AM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Dec 2nd, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Dec 2nd, 2020 12:04PM Dec 2nd, 2020 12:04PM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Dec 1st, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Dec 1st, 2020 10:39AM Dec 1st, 2020 10:39AM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Nov 30th, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Nov 30th, 2020 10:57AM Nov 30th, 2020 10:57AM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Nov 29th, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Nov 29th, 2020 05:42PM Nov 29th, 2020 05:42PM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Nov 28th, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Nov 28th, 2020 01:35PM Nov 28th, 2020 01:35PM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Nov 27th, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Nov 27th, 2020 09:55AM Nov 27th, 2020 09:55AM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Nov 26th, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Nov 26th, 2020 10:56AM Nov 26th, 2020 10:56AM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Nov 25th, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Nov 25th, 2020 01:52PM Nov 25th, 2020 01:52PM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology
private:criticaldiagnostics 2707190 Nov 24th, 2020 12:00AM Critical Diagnostics 370 7.00 Open Biotechnology Nov 24th, 2020 10:04AM Nov 24th, 2020 10:04AM Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occur in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death (SCD), and to progression of heart failure. The Presage® ST2 Assay quantitatively measures the concentration of soluble ST2, providing a physician with an accurate tool to assess prognosis in patients with heart failure. The Presage® ST2 Assay helps clinicians assess patient prognosis in order to better personalize their care. By selecting the most appropriate treatments and interventions for each patient, a physician can maximize the clinical benefit from increasingly limited healthcare resources. Critical Diagnostics is headquartered in San Diego, California. Presage is cleared for use in the risk stratification of chronic heart failure. Any comments or discussions by individuals outside of the above indications for use is not endorsed by Critical Diagnostics and shall not imply that Presage is cleared for indications beyond what is stated above. Open Professional Diagnostics, Cardiac Diseases, Cardiac biomarker Open San Diego US Critical Diagnostics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.